Q32 Bio Inc. (QTTB) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
7.48
↑+1530% vs avg
5yr avg: 0.46
30Y Low0.5·High0.5
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.72
+17% vs avg
5yr avg: 3.18
30Y Low1.0·High7.4
ROE
↑
125.1%
↓+151% vs avg
5yr avg: -247.1%
30Y Low-220%·High125%
Debt/EBITDA
0.89
+0% vs avg
5yr avg: 0.89
30Y Low0.9·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
QTTB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Q32 Bio Inc. trades at 5.2x earnings, 283% above its 5-year average of 1.4x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.1x, the stock trades at a discount of 77%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $162M | $41M | $42M | $35M | $72M | $201M | $518M | $872M | $638M | — | — |
| Enterprise Value | $129M | $8M | $-17104204 | $60M | $73M | $117M | $316M | $818M | $600M | — | — |
| P/E Ratio → | 5.25 | 1.37 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.02 | 0.76 | — | — | 10.87 | 5.92 | 191.83 | 523.31 | 119.96 | — | — |
| P/B Ratio | 3.72 | 0.97 | 7.39 | — | — | 1.19 | 2.64 | 3.37 | 3.25 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
QTTB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Q32 Bio Inc.'s enterprise value stands at 7.5x EBITDA, 1530% above its 5-year average of 0.5x. The Healthcare sector median is 14.4x, placing the stock at a 48% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.15 | — | — | 11.00 | 3.44 | 117.08 | 491.03 | 112.78 | — | — |
| EV / EBITDA | 7.48 | 0.46 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 7.65 | 0.47 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
QTTB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Q32 Bio Inc. earns an operating margin of 31.5%. Operating margins have compressed from 725.5% to 31.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 125.1% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.3% | 99.3% | — | 100.0% | 100.0% | 71.9% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | 31.5% | 31.5% | — | 725.5% | -589.8% | -282.4% | -4821.0% | -6599.2% | -1126.0% | — | — |
| Net Profit Margin | 55.5% | 55.5% | — | 808.0% | -643.6% | -281.9% | -4762.9% | -6237.5% | -1044.3% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 125.1% | 125.1% | -841.1% | — | -219.9% | -52.4% | -56.6% | -45.7% | -37.7% | -56.7% | -107.3% |
| ROA | 38.7% | 38.7% | -68.5% | -98.8% | -31.3% | -40.3% | -44.8% | -36.5% | -28.0% | -39.5% | -56.6% |
| ROIC | — | — | — | — | — | -181.7% | -98.3% | -45.4% | -43.9% | -103.8% | — |
| ROCE | 26.8% | 26.8% | -121.5% | -261.8% | -39.5% | -44.1% | -48.3% | -41.1% | -32.8% | -43.5% | -127.5% |
QTTB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Q32 Bio Inc. carries a Debt/EBITDA ratio of 0.9x, which is very conservative (72% below the sector average of 3.2x). The company holds a net cash position — cash of $48M exceeds total debt of $15M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 15.4x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 3.33 | — | — | 0.14 | 0.08 | — | — | — | — |
| Debt / EBITDA | 0.89 | 0.89 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.78 | -10.41 | — | — | -0.50 | -1.03 | -0.21 | -0.19 | -0.52 | -1.52 |
| Net Debt / EBITDA | -1.91 | -1.91 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -11.41 | — |
| Interest Coverage | 15.37 | 15.37 | -152.62 | — | — | — | — | — | — | — | — |
Net cash position: cash ($48M) exceeds total debt ($15M)
QTTB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Q32 Bio Inc.'s current ratio of 4.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.04x to 4.85x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | 4.85 | 4.97 | 2.04 | 0.81 | 11.14 | 9.69 | 21.54 | 9.84 | 14.85 | 1.88 |
| Quick Ratio | 4.85 | 4.85 | 4.97 | 2.04 | 0.78 | 11.14 | 9.69 | 21.54 | 9.84 | 14.85 | 1.88 |
| Cash Ratio | 4.26 | 4.26 | 4.74 | 1.82 | 0.76 | 9.05 | 9.60 | 21.20 | 9.54 | 14.63 | 1.79 |
| Asset Turnover | — | 0.87 | — | -0.14 | 0.11 | 0.16 | 0.01 | 0.01 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | -41.43 | 58.39 | — | 54.03 | 87.64 | 54.87 | — | — |
QTTB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Q32 Bio Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 19.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 19.1% | 72.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $12M | $12M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M |
Peer Comparison
Compare QTTB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 QTTBYou | $162M | 5.2 | 7.5 | — | 99.3% | 31.5% | 125.1% | — | 0.9 |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 TERN | $5B | -51.4 | — | — | — | — | -14.2% | -24.7% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 ALNY | $39B | 124.2 | 68.6 | 83.0 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 REGN | $64B | 14.7 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 SANA | $771M | -2.9 | — | — | — | — | -118.7% | -74.4% | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
What if you invested $1,000 in QTTB 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in QTTB be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs QTTB Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationQTTB vs AKRO — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Akero Therapeutics, Inc..
Compare NowQTTB — Frequently Asked Questions
Quick answers to the most common questions about buying QTTB stock.
What is Q32 Bio Inc.'s P/E ratio?
Q32 Bio Inc.'s current P/E ratio is 5.2x. The historical average is 1.4x. This places it at the 100th percentile of its historical range.
What is Q32 Bio Inc.'s EV/EBITDA?
Q32 Bio Inc.'s current EV/EBITDA is 7.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 0.5x.
What is Q32 Bio Inc.'s ROE?
Q32 Bio Inc.'s return on equity (ROE) is 125.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -56.4%.
Is QTTB stock overvalued?
Based on historical data, Q32 Bio Inc. is trading at a P/E of 5.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Q32 Bio Inc.'s profit margins?
Q32 Bio Inc. has 99.3% gross margin and 31.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Q32 Bio Inc. have?
Q32 Bio Inc.'s Debt/EBITDA ratio is 0.9x, indicating low leverage. A ratio below 2x is generally considered financially healthy.